Advances in Primary Biliary Cholangitis: Expert Insights on Emerging Data and Key Treatment Innovations - Episode 8

The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data

Published on: February 16, 2026

Frances Lee, MD, Aparna Goel, MD, A. Sidney Barritt IV, MD, MSCR, Lance L. Stein, MD

Explore the safety and long-term effects of PPAR agonists in patients with liver disease, addressing concerns about bone health and medication interactions.

EP. 1: An Overview of PBC Pathophysiology, Severity, and Burden

EP. 2: Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health

EP. 3: Assessing Disease Severity and Progression Risk in PBC

EP. 4: Diagnostic Criteria in PBC: What Clinicians are Looking For

EP. 5: Experts Review the First- and Second-Line Treatment Options for PBC

EP. 6: How Special Populations and Disease Risk Impact Treatment Assessment in PBC

EP. 7: The Efficacy of PPAR Agonists in PBC: Signals of Extrahepatic Improvements

Now Viewing

EP. 8: The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data

In this episode, “The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data” the expert hepatologists explore key safety data from the ELATIVE trial on elafibranor and from RESPONSE on seladelpar.

Led by the moderator, the panelists examine the following critical question:

What have we learned about the safety of PPAR agonists from the primary trials of elafibranor (ELATIVE) and seladelpar (RESPONSE)?

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, “Addressing Fatigue: Traditional Management Outside Primary Therapy,” features the panelists advancing their conversation on PBC and focusing on how they typically manage patient fatigue beyond primary therapies. They discuss how to coach patients into beneficial health and wellness routines to reduce fatigue, and stress the importance of a regular sleeping schedule.